Patents by Inventor Tony Yantao Zhang

Tony Yantao Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952364
    Abstract: A group of tropomyosin receptor kinase inhibitors including an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: April 9, 2024
    Assignee: TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
    Inventors: Boyu Zhong, Tony Yantao Zhang, Yiju Cao, Guangming Chen
  • Patent number: 11918692
    Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: March 5, 2024
    Assignee: Eli Lilly and Company
    Inventors: Matthew Carl Allgeier, Tony Yantao Zhang
  • Publication number: 20240059729
    Abstract: The present invention relates to a multifunctional cyclic-dinucleotide compound of formula (X) and its derivatives, which can be used as a prodrug of an apoptosis inducer or a cytotoxic agent for inducing cell apoptosis or anti-virus, and can also regulate immunity pathway to generate a therapeutically beneficial immune response. The present disclosure further relates to pharmaceutical compositions and pharmaceutical combinations comprising the cyclic-dinucleotide compounds of the present invention, methods for synthesizing them, and medical uses thereof.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 22, 2024
    Applicant: TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
    Inventors: Tony Yantao ZHANG, Li QU, Liang LOU, Puji ZHENG, Fei LV
  • Publication number: 20240018159
    Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
    Type: Application
    Filed: August 22, 2023
    Publication date: January 18, 2024
    Inventors: Gang QIN, Tony Yantao ZHANG, Guangming CHEN, Paul H. SONG, Boyu ZHONG, Mingyu HU
  • Publication number: 20230406849
    Abstract: Compounds which have the structure represented by formula (I) and can be used as KRas inhibitors, pharmaceutical compositions comprising this type of compounds, a method of preparing this type of compounds, and uses of these compounds in the treatment of cancers.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 21, 2023
    Applicant: TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
    Inventors: Erchang SHANG, Boyu ZHONG, Tony Yantao ZHANG, Guanglin SONG, Ruixiang WANG, Bingqing TANG, Xubo HU
  • Patent number: 11814394
    Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: November 14, 2023
    Assignee: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
    Inventors: Gang Qin, Tony Yantao Zhang, Guangming Chen, Paul H. Song, Boyu Zhong, Mingyu Hu
  • Publication number: 20230271977
    Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
    Type: Application
    Filed: November 8, 2022
    Publication date: August 31, 2023
    Inventors: Gang QIN, Tony Yantao ZHANG, Guangming CHEN, Paul H. SONG, Boyu ZHONG, Mingyu HU
  • Publication number: 20220388983
    Abstract: A group of tropomyosin receptor kinase inhibitors including an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.
    Type: Application
    Filed: September 3, 2019
    Publication date: December 8, 2022
    Applicant: TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
    Inventors: Boyu ZHONG, Tony Yantao ZHANG, Yiju CAO, Guangming CHEN
  • Publication number: 20220287978
    Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
    Type: Application
    Filed: June 1, 2022
    Publication date: September 15, 2022
    Inventors: Matthew Carl ALLGEIER, Tony Yantao ZHANG
  • Patent number: 11376223
    Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: July 5, 2022
    Assignee: Eli Lilly and Company
    Inventors: Matthew Carl Allgeier, Tony Yantao Zhang
  • Publication number: 20210137842
    Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
    Type: Application
    Filed: July 10, 2018
    Publication date: May 13, 2021
    Inventors: Matthew Carl ALLGEIER, Tony Yantao ZHANG
  • Patent number: 8124776
    Abstract: The present invention provides for novel compounds of formula I wherein X is S or S(O); R1 and R2 are each independently selected from the group consisting of —CH2CH3 and phenyl; or R1 and R2 combine to form morpholino; and processes to prepare arzoxifene.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: February 28, 2012
    Assignee: Eli Lilly and Company
    Inventors: Charles Arthur Alt, Douglas Patton Kjell, Tony Yantao Zhang, Fu-Yao Zhang, Jared Wade Fennell, Kevin Dale Seibert
  • Publication number: 20100137602
    Abstract: The present invention provides for novel compounds of formula I wherein X is S or S(O); R1 and R2 are each independently selected from the group consisting of —CH2CH3 and phenyl; or R1 and R2 combine to form morpholino; and processes to prepare arzoxifene.
    Type: Application
    Filed: March 3, 2008
    Publication date: June 3, 2010
    Inventors: Charles Arthur Alt, Douglas Patton Kjell, Tony Yantao Zhang, Fu-Yao Zhang, Jared Wade Fennell, Kevin Dale Siebert
  • Patent number: 7309702
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: December 18, 2007
    Assignees: Avera Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang, Jeffrey Forrester McKelvy
  • Patent number: 7045628
    Abstract: The present invention relates to a one-pot process for preparing a compound of formula I: I; by reacting a compound of formula II with a compound of formula III: in the presence of a suitable solvent, a suitable base, a palladium catalyst and a suitable ligand.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: May 16, 2006
    Assignee: Eli Lilly and Company
    Inventors: Scott Allan May, Thomas Michael Wilson, Tony Yantao Zhang
  • Patent number: 7001908
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: February 21, 2006
    Assignees: Avera Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Patent number: 6946579
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: September 20, 2005
    Assignee: Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Publication number: 20040133047
    Abstract: The present invention relates to a one-pot process for preparing a compound of formula I: I; by reacting a compound of formula II with a compound of formula III: in the presence of a suitable solvent, a suitable base, a palladium catalyst and a suitable ligand.
    Type: Application
    Filed: May 20, 2003
    Publication date: July 8, 2004
    Inventors: Scott Allan May, Thomas Michael Wilson, Tony Yantao Zhang
  • Publication number: 20040049083
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Application
    Filed: July 2, 2003
    Publication date: March 11, 2004
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Publication number: 20040044009
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Application
    Filed: April 16, 2003
    Publication date: March 4, 2004
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang